Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 08, 2018 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Presents Clinical Data on DCCR at 2018 Foundation for Prader-Willi Research Annual Conference

Oral presentation on DCCR’s mechanism of action in treating hyperphagia Poster presentation on DCCR’s safety profile and implications for PWS Phase III study design REDWOOD CITY, Calif., Oct. 08,...
October 01, 2018 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Presents Clinical Data on DCCR at Late-Breaking Session of European Society for Paediatric Endocrinology

Pharmacokinetic data supports once-daily dosingLong-term use of DCCR not associated with compromised glycemic control REDWOOD CITY, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics,...
September 19, 2018 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease

REDWOOD CITY, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
September 17, 2018 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics to Present DCCR Clinical Data at Late Breaking Sessions of the European Society for Paediatric Endocrinology

REDWOOD CITY, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
September 06, 2018 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Expansion of Ongoing Phase III Trial of DCCR in Prader-Willi Syndrome to Include Younger Patients

Amendment Lowers Minimum Age Inclusion Criteria to Four Years, from Eight Years, to Better Reflect Demographics of PWS Population Top-line Data from Phase III Trial Expected in First Half of 2019 ...
September 04, 2018 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Low Lean Body Mass in Prader-Willi Syndrome

REDWOOD CITY, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
August 14, 2018 16:05 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results

REDWOOD CITY, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
July 30, 2018 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Receives Fast Track Designation from FDA for DCCR for Treatment of Prader-Willi Syndrome

Phase III Clinical Trial Ongoing at Multiple Sites in the U.S. REDWOOD CITY, Calif., July 30, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage...
June 04, 2018 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics To Present Corporate Update at the BIO International Convention

REDWOOD CITY, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
May 16, 2018 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results

REDWOOD CITY, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...